Coherus BioSciences (CHRS) Tops Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall St rises as AI momentum holds heading into key earnings, Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.05 +3.96%
Revenue Growth %: +37.8%
Financial Fact:
Income tax provision/(benefit): 6.81M
Today's EPS Names:
OMID, SICP, SCKT, More
Revenue Growth %: +37.8%
Financial Fact:
Income tax provision/(benefit): 6.81M
Today's EPS Names:
OMID, SICP, SCKT, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q4 EPS of ($0.28), $0.02 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $54.14 million versus the consensus estimate of $44.15 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ASM International posts Q3 net income of €308.1m, raises 2027 revenue target
- Visionstate and ELi Technology Sign Strategic Collaboration Agreement to Advance Location-Aware Facility Management
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
